SCHEMBL14599459

SCHEMBL14599459

COc1cc2nccc(N3CCC(CC(=O)Nc4ccc(C(C)C)cc4)CC3)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.54
KIT P10721 3/20 0.54
PDGFRA P16234 3/20 0.54
FLT3 P36888 2/20 0.54
ENPP1 P22413 1/20 0.54
NCF1 P14598 1/20 0.48
FGFR2 P21802 1/20 0.46
HTR1A P08908 2/20 0.45
HTR7 P34969 2/20 0.45
EHMT2 Q96KQ7 4/20 0.44
EHMT1 Q9H9B1 4/20 0.44
ADRA2A P08913 2/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
PDE4B Q07343 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4966763 0.88 ENPP1 (0.71) PDGFRBKITPDGFRAFLT3ENPP1
SCHEMBL4972356 0.86 PDGFRB (0.66) PDGFRBKITPDGFRAFLT3ENPP1
SCHEMBL14599467 0.86 KIT (0.58) PDGFRBKITPDGFRAFLT3NCF1
SCHEMBL22300094 0.77 NCF1 (0.59) PDGFRBENPP1NCF1HTR1AHTR7
SCHEMBL22291005 0.77 NCF1 (0.67) PDGFRBENPP1NCF1FGFR2HTR1A
SCHEMBL17729157 0.76 CHRM4 (0.48)
SCHEMBL5528019 0.75 PDGFRB (0.69) PDGFRBKITPDGFRAFLT3ENPP1
SCHEMBL4969179 0.75 PDGFRB (0.69) PDGFRBKITPDGFRAFLT3ENPP1
SCHEMBL30446792 0.75 NCF1 (0.65) PDGFRBENPP1NCF1HTR1AHTR7
SCHEMBL4966832 0.75 PDGFRB (0.71) PDGFRBKITPDGFRAFLT3ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDGFRB 51/4885KIT 104/4885PDGFRA 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.